$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000162828022004085 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.470M	$22.92M	$2.210M
YoY Change	238.01%	187.58%	-12.65%
% of Gross Profit
Research & Development	$7.102M	$35.11M	$1.590M
YoY Change	346.67%	452.53%	-9.14%
% of Gross Profit
Depreciation & Amortization	$78.00K	$200.0K	$40.00K
YoY Change	95.0%	100.0%	33.33%
% of Gross Profit
Operating Expenses	$14.57M	$58.03M	$3.810M
YoY Change	282.47%	172.07%	-10.98%
Operating Profit		-$58.03M
YoY Change		172.62%
Interest Expense	-$35.00K	$79.00K	-$170.0K
YoY Change	-79.41%	-89.04%	-101.02%
% of Operating Profit
Other Income/Expense, Net	$26.00K	-$389.0K	$180.0K
YoY Change	-85.56%	-27.56%	-700.0%
Pretax Income	-$14.58M	-$58.40M	-$3.790M
YoY Change	284.72%	167.89%	-130.61%
Income Tax	$0.00	-$100.0K
% Of Pretax Income
Net Earnings	-$14.58M	-$58.37M	-$3.790M
YoY Change	284.72%	167.46%	-130.61%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.30
Diluted Earnings Per Share	-$73.18K	-$0.30	-$22.21K
COMMON SHARES
Basic Shares Outstanding	199.2M shares	195.0M shares	162.0M shares
Diluted Shares Outstanding		195.0M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.96M	$94.96M	$24.04M
YoY Change	295.0%	295.0%	223.12%
Cash & Equivalents	$94.96M	$94.96M	$24.04M
Short-Term Investments	$0.00
Other Short-Term Assets	$7.688M	$7.688M	$1.840M
YoY Change	317.83%	317.83%	-77.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$102.6M	$102.6M	$25.88M
YoY Change	296.65%	296.62%	64.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.164M	$2.751M	$633.0K
YoY Change	83.89%	157.1%	184.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.800M	$364.0K	$714.0K
YoY Change	152.1%	-15.35%	6.93%
Total Long-Term Assets	$3.115M	$3.115M	$1.498M
YoY Change	107.94%	107.67%	43.87%
TOTAL ASSETS
Total Short-Term Assets	$102.6M	$102.6M	$25.88M
Total Long-Term Assets	$3.115M	$3.115M	$1.498M
Total Assets	$105.8M	$105.8M	$27.38M
YoY Change	286.33%	286.27%	62.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.312M	$2.312M	$395.0K
YoY Change	485.32%	478.0%	-79.16%
Accrued Expenses	$4.325M	$4.688M	$2.930M
YoY Change	47.59%	57.85%	29.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$234.0K
YoY Change	-100.0%
Long-Term Debt Due	$0.00	$0.00	$230.0K
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$7.000M	$7.000M	$3.614M
YoY Change	93.69%	93.91%	-20.47%
LONG-TERM LIABILITIES
Long-Term Debt	$1.712M	$1.712M	$1.823M
YoY Change	-6.09%	-5.93%	70.04%
Other Long-Term Liabilities	$1.231M	$1.231M	$0.00
YoY Change		215.64%	-100.0%
Total Long-Term Liabilities	$2.943M	$2.943M	$2.212M
YoY Change	33.05%	33.17%	77.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.000M	$7.000M	$3.614M
Total Long-Term Liabilities	$2.943M	$2.943M	$2.212M
Total Liabilities	$9.943M	$9.943M	$5.826M
YoY Change	70.67%	70.55%	0.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$131.7M		-$73.30M
YoY Change	79.62%		42.39%
Common Stock	$1.995M		$1.841M
YoY Change	8.37%		249.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$48.00K		$48.00K
YoY Change	0.0%		0.28%
Treasury Stock Shares
Shareholders Equity	$95.82M	$95.82M	$21.55M
YoY Change
Total Liabilities & Shareholders Equity	$105.8M	$105.8M	$27.38M
YoY Change	286.33%	286.27%	62.88%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$14.58M	-$58.37M	-$3.790M
YoY Change	284.72%	167.46%	-130.61%
Depreciation, Depletion And Amortization	$78.00K	$200.0K	$40.00K
YoY Change	95.0%	100.0%	33.33%
Cash From Operating Activities	-$12.80M	-$47.94M	-$4.280M
YoY Change	199.16%	225.93%	-51.03%
INVESTING ACTIVITIES
Capital Expenditures	-$192.0K	$939.0K	-$250.0K
YoY Change	-23.2%	205.86%	733.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$750.0K	$0.00
YoY Change
Cash From Investing Activities	-$192.0K	-$1.816M	-$250.0K
YoY Change	-23.2%	491.53%	1150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$129.2M
YoY Change		241.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	605.0K	$120.7M	9.470M
YoY Change	-93.61%	281.75%	940.66%
NET CHANGE
Cash From Operating Activities	-12.80M	-$47.94M	-4.280M
Cash From Investing Activities	-192.0K	-$1.816M	-250.0K
Cash From Financing Activities	605.0K	$120.7M	9.470M
Net Change In Cash	-12.39M	$70.92M	4.940M
YoY Change	-350.83%	327.35%	-162.93%
FREE CASH FLOW
Cash From Operating Activities	-$12.80M	-$47.94M	-$4.280M
Capital Expenditures	-$192.0K	$939.0K	-$250.0K
Free Cash Flow	-$12.61M	-$48.88M	-$4.030M
YoY Change	212.95%	225.52%	-53.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36751
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	263 Great Valley Parkway
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2021	dei	City Area Code CityAreaCode	484
CY2021	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	OCGN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1600000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	199488183	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94958000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24039000	USD
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	4988000	USD
CY2020Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	0	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2700000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	102646000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	25878000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1164000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	633000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1800000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	714000	USD
CY2021Q4	us-gaap	Assets Assets	105761000	USD
CY2020Q4	us-gaap	Assets Assets	27376000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2312000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	395000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4325000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2941000	USD
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	234000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3614000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1712000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1823000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2943000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2212000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	9943000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	5826000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	199502183	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184133384	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	199380683	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184011884	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1995000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1841000	USD
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	225537000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93059000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131667000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73302000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95818000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105761000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27376000	USD
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	USD
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	43000	USD
CY2019	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	USD
CY2021	us-gaap	Revenues Revenues	0	USD
CY2020	us-gaap	Revenues Revenues	43000	USD
CY2019	us-gaap	Revenues Revenues	0	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35108000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6354000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8086000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22920000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7974000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6077000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	58028000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	21328000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	14163000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-58028000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-21285000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-14163000	USD
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187000	USD
CY2021	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2020	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341000	USD
CY2021	us-gaap	Interest Expense InterestExpense	79000	USD
CY2020	us-gaap	Interest Expense InterestExpense	721000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1768000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-310000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	184000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-784000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-389000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-537000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6080000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58417000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21822000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20243000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-52000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58365000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21822000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21822000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20243000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20243000	USD
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12546000	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58365000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34368000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20243000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	195013043	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	195013043	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112236110	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112236110	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13893819	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13893819	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-12709000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13980000	USD
CY2019	ocgn	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	11256000	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	48000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20243000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11019000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	660000	USD
CY2020	ocgn	Stock Issued During Period Value Warrant Exchange StockIssuedDuringPeriodValueWarrantExchange	-4978000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21822000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6958000	USD
CY2021	ocgn	Stock Issued During Period Value Options And Warrants Exercised StockIssuedDuringPeriodValueOptionsAndWarrantsExercised	1262000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95818000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-58365000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-21822000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-20243000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	229000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	102000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	61000	USD
CY2021	ocgn	Non Cash Interest Expense NonCashInterestExpense	78000	USD
CY2020	ocgn	Non Cash Interest Expense NonCashInterestExpense	721000	USD
CY2019	ocgn	Non Cash Interest Expense NonCashInterestExpense	1734000	USD
CY2021	ocgn	Noncash Lease Expense NoncashLeaseExpense	360000	USD
CY2020	ocgn	Noncash Lease Expense NoncashLeaseExpense	189000	USD
CY2019	ocgn	Noncash Lease Expense NoncashLeaseExpense	250000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	USD
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-3187000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6958000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	660000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884000	USD
CY2021	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2020	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	0	USD
CY2019	ocgn	Gains Losses On Conversion Of Debt GainsLossesOnConversionOfDebt	-341000	USD
CY2021	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-52000	USD
CY2020	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	0	USD
CY2019	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	426000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	761000	USD
CY2020	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	USD
CY2019	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	349000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	742000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	370000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1007000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3498000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-541000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1629000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-100000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	104000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	227000	USD
CY2021	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-366000	USD
CY2020	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-195000	USD
CY2019	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-249000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47941000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14709000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16893000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	939000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	307000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000	USD
CY2021	ocgn	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	127000	USD
CY2020	ocgn	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	USD
CY2019	ocgn	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	2327000	USD
CY2021	ocgn	Issuance Of Financing Receivable IssuanceOfFinancingReceivable	750000	USD
CY2020	ocgn	Issuance Of Financing Receivable IssuanceOfFinancingReceivable	0	USD
CY2019	ocgn	Issuance Of Financing Receivable IssuanceOfFinancingReceivable	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1816000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-307000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2357000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	129211000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37822000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1183000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	8525000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1477000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	48000	USD
CY2021	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	0	USD
CY2020	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	0	USD
CY2019	ocgn	Proceeds From Pre Merger Financing Financing Activities ProceedsFromPreMergerFinancingFinancingActivities	22546000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	921000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6800000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	99000	USD
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	5625000	USD
CY2021	ocgn	Vaccination Dose Regimen Duration Apart VaccinationDoseRegimenDurationApart	P28D
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	5290000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	24000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120676000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31611000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25066000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70919000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16595000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5816000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1779000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95109000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595000	USD
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	603000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4988000	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2021	ocgn	Gain Loss On Forgiveness Of Paycheck Protection Program Note GainLossOnForgivenessOfPaycheckProtectionProgramNote	426000	USD
CY2020	ocgn	Gain Loss On Forgiveness Of Paycheck Protection Program Note GainLossOnForgivenessOfPaycheckProtectionProgramNote	0	USD
CY2019	ocgn	Gain Loss On Forgiveness Of Paycheck Protection Program Note GainLossOnForgivenessOfPaycheckProtectionProgramNote	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	214000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	1226000	USD
CY2020	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	180000	USD
CY2019	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	470000	USD
CY2021	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2020	us-gaap	Notes Issued1 NotesIssued1	5625000	USD
CY2019	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	331000	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2019	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	13980000	USD
CY2021	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	4000	USD
CY2019	ocgn	Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction	1150000	USD
CY2021	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0	USD
CY2020	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	0	USD
CY2019	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	2253000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The Company is headquartered in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Vaccine Candidate</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited ("Bharat Biotech"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech’s intellectual property rights, with the right to grant sublicenses, to develop, manufacture, and commercialize COVAXIN for the prevention of COVID-19 caused by SARS-CoV-2 in the United States, its territories, and possessions. In June 2021, the Company entered into an amendment to the Co-Development, Supply and Commercialization Agreement (as so amended, the "Covaxin Agreement") pursuant to which the parties agreed to expand the Company's rights to develop, manufacture, and commercialize COVAXIN to include Canada in addition to the United States, its territories, and possessions (the "Ocugen Covaxin Territory").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant. COVAXIN requires a two-dose vaccination regimen given 28 days apart and is stored in standard vaccine storage conditions (2-8°C). COVAXIN was granted an Emergency Use Listing by the World Health Organization in November 2021. Over 295 million doses globally have been administered to date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is pursuing Biologics License Application ("BLA") approval for COVAXIN in the United States based upon the recommendation of the U.S. Food and Drug Administration ("FDA"). In October 2021, the Company submitted an Investigational New Drug ("IND") application to the FDA to initiate a Phase 2/3 immuno-bridging and broadening clinical trial evaluating COVAXIN for adults ages 18 years and older. The clinical trial is designed to evaluate whether the immune response experienced in participants in a completed Phase 3 clinical trial in India is similar to a demographically representative, adult population in the United States. In November 2021, the Company was notified that the FDA issued a clinical hold on its IND application. In December 2021, the FDA sent the Company a letter setting forth the reasons for the clinical hold and specific guidance on steps that must be taken to have the clinical hold lifted. The Company provided the FDA responses to their comments and the FDA lifted its clinical hold in February 2022. The Company plans to initiate the Phase 2/3 immuno-bridging and broadening clinical trial for COVAXIN as soon as the Company is able to. The Company also plans to initiate a safety-bridging clinical trial in the first half of 2022, subject to discussions with the FDA. Subject to the foregoing, the Company anticipates submitting a BLA with the FDA near the end of 2022. In November 2021, the Company also submitted a request to the FDA for Emergency Use Authorization ("EUA") for COVAXIN for pediatric use in ages two to 18 years in the United States. The EUA submission was based on the results of a Phase 2/3 immuno-bridging pediatric clinical trial conducted by Bharat Biotech in India. The Company's EUA submission is currently under review by the FDA. In February 2022, Delta and Omicron neutralization results along with a safety database of more than 36 million teenagers who had been vaccinated with COVAXIN were submitted to the FDA to support the Company's EUA submission.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also pursuing approval for COVAXIN in Canada. In July 2021, the Company completed its rolling submission to Health Canada for COVAXIN. The rolling submission process, which permits companies to submit safety and efficacy data and information as they become available, was recommended and accepted under the Minister of Health’s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and transitioned to a New Drug Submission ("NDS") for COVID-19. The submission was conducted through the Company's Canadian subsidiary, Vaccigen Ltd. The Company is in discussions with Health Canada regarding its NDS submission for COVAXIN. In December 2021, the Company was provided with a Notice of Deficiency ("NOD") from Health Canada regarding its NDS submission. Health Canada requested further analyses of the COVAXIN preclinical and clinical data, as well as additional information regarding chemistry, manufacturing, and controls ("CMC"). The Company has responded to and provided proposed resolutions for the deficiencies included in the NOD. The Company's responses are currently under review by Health Canada. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is evaluating its commercialization strategy for COVAXIN in the United States and Canada, if authorized or approved in either jurisdiction. In June 2021, the Company selected Jubilant HollisterStier as its manufacturing partner for COVAXIN to prepare for the potential commercial manufacturing for the Ocugen Covaxin Territory. The Company expects to </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enter into a master services agreement with Jubilant HollisterStier for the commercial manufacture of COVAXIN. The technology transfer process from Bharat Biotech to Jubilant HollisterStier for drug product manufacturing has been initiated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a Development and Commercial Supply Agreement (the “Supply Agreement”) with Bharat Biotech, pursuant to which Bharat Biotech will supply the Company with clinical trial materials and commercial supplies of COVAXIN finished drug product prior to the completion of a technology transfer. Following the completion of a technology transfer, Bharat Biotech will supply COVAXIN drug product components and continue to supply finished drug product as necessary for the commercial manufacture and supply of COVAXIN subsequent to a regulatory authorization or approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is developing a modifier gene therapy platform designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs"), such as retinitis pigmentosa ("RP") and Leber congenital amaurosis ("LCA"), and dry age-related macular degeneration ("AMD"). The Company's modifier gene therapy platform is based on Nuclear Hormone Receptors ("NHRs"), which have the potential to restore homeostasis, the basic biological processes in the retina. The modifier gene therapy platform, through its use of NHRs, represents a novel approach that has the potential to address multiple retinal diseases caused by mutations in multiple genes with one product; and potentially address complex diseases, such as dry AMD, that are potentially caused by imbalances in multiple gene networks.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that OCU400, its first product candidate being developed with its modifier gene therapy platform, has the potential to be broadly effective in restoring retinal integrity and function across a range of IRDs, including RP and LCA. OCU400 has received four Orphan Drug Designations from the FDA for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"NR2E3"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), centrosomal protein 290 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"CEP290"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), rhodopsin (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"RHO"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and phosphodiesterase 6B (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"PDE6ß"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) mutation-associated inherited retinal degenerations. In November 2021, the Company submitted an IND application to the FDA for OCU400 for the treatment of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease genotypes. The Company's IND application was accepted by the FDA in December 2021. The Company has initiated a Phase 1/2 clinical trial in the United States for the treatment of these disease genotypes and the first patient is expected to be dosed in the first half of 2022. This Phase 1/2 clinical trial is a multicenter, open-label, dose ranging study to assess the safety of unilateral subretinal administration of OCU400 in subjects with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related RP. OCU400 has additionally received Orphan Medicinal Product Designation from the European Commission, based on the recommendation of the European Medicines Agency, for RP and LCA. The Company believes OCU400 has the potential for broad spectrum applications to treat many IRDs. The Company is currently evaluating options to initiate OCU400 clinical trials in Europe.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"RORA"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of dry AMD. The Company is currently executing pre-IND studies consistent with FDA discussions to support a Phase 1/2 clinical trial. The Company has engaged CanSino Biologics, Inc. ("CanSinoBIO") to manufacture clinical supplies and be responsible for the CMC development for OCU400 and OCU410. See Note 3 for additional information about the Company's collaboration with CanSinoBIO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's pipeline also includes a biologic product candidate, OCU200, a novel fusion protein designed to treat severely sight-threatening diseases such as diabetic macular edema, diabetic retinopathy, and wet AMD. The Company is currently establishing a current Good Manufacturing Practice process for the production of clinical trial materials and executing pre-IND studies consistent with FDA discussions to support a Phase 1/2a clinical trial. The Company has completed the technology transfer of manufacturing processes to its contract development and manufacturing organization that will manufacture OCU200 clinical supplies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. The Company incurred net losses of approximately $58.4 million, $21.8 million, and $20.2 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of $131.7 million and cash, cash equivalents, and restricted cash totaling $95.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks, expenses, and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research, development, and commercialization efforts for its product candidates, which will </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require significant additional funding. If the Company is unable to obtain additional financing in the future or its research, development, and commercialization efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, or other funding from the government or other third parties. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital, or appropriately manage certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to research, develop, and commercialize the Company’s product candidates and the uncertainty of futures revenues associated with COVAXIN, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	ocgn	Number Of Vaccination Dose Regimen NumberOfVaccinationDoseRegimen	2	dose
CY2021	ocgn	Number Of Vaccination Doses Administered Globally NumberOfVaccinationDosesAdministeredGlobally	295000000	dose
CY2021	ocgn	Number Of Orphan Drug Designations NumberOfOrphanDrugDesignations	4	orphan_drug_designation
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58400000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21800000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20200000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131700000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95100000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, debt and equity instruments (including derivative liabilities), asset held for sale, and the collectibility of the note receivable.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94958000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24039000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95109000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190000	USD
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000	USD
CY2020Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	7000000	USD
CY2019	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1100000	shares
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	1538000	USD
CY2021Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	800000	USD
CY2021Q2	ocgn	Financing Receivable Interest Rate Stated Percentage FinancingReceivableInterestRateStatedPercentage	0.05
CY2021Q3	ocgn	Financing Receivable Interest Rate Stated Percentage FinancingReceivableInterestRateStatedPercentage	0.09
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	64000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	859000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	374000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	226000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1164000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	633000	USD
CY2021	us-gaap	Depreciation Depreciation	200000	USD
CY2020	us-gaap	Depreciation Depreciation	100000	USD
CY2019	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2020Q4	ocgn	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	1	segment
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	360000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	189000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	250000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	105000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	85000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	80000	USD
CY2021	us-gaap	Lease Cost LeaseCost	465000	USD
CY2020	us-gaap	Lease Cost LeaseCost	274000	USD
CY2019	us-gaap	Lease Cost LeaseCost	330000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	434000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	44000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	389000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1594000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	433000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	440000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	261000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	269000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	277000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	285000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	293000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1825000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	231000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1594000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2021Q4	ocgn	Base Rent Payments Expected Cost BaseRentPaymentsExpectedCost	3800000	USD
CY2021Q4	ocgn	Number Of Additional Lease Agreement Extensions NumberOfAdditionalLeaseAgreementExtensions	2	extension
CY2021Q4	ocgn	Lessee Operating Lease Term Of Contract For Additional Lease Agreement LesseeOperatingLeaseTermOfContractForAdditionalLeaseAgreement	P5Y
CY2021Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	866000	USD
CY2020Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	512000	USD
CY2021Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	703000	USD
CY2020Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	117000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	747000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	405000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1716000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	963000	USD
CY2021Q4	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	0	USD
CY2020Q4	ocgn	Accrued Severance Related Liabilities Current AccruedSeveranceRelatedLiabilitiesCurrent	712000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	232000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4325000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2941000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	884000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12600000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2021Q4	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	equityCompensationPlan
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	1712000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	2057000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
	ocgn	Number Of At The Market Offerings NumberOfAtTheMarketOfferings	3	at-the-marketOffering
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6958000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	660000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.87
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2600000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	900000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58400000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21800000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20200000	USD
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.075
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.028
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2021	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.001
CY2020	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.010
CY2019	ocgn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	0.081
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.029
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.319
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.314
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.243
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52038000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35714000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298000	USD
CY2021Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11235000	USD
CY2020Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11235000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	448000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	398000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1960000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2285000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2064000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1290000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4350000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2541000	USD
CY2021Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	461000	USD
CY2020Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	125000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79854000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	60886000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	79395000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60761000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	459000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	125000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	459000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	125000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18600000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	131800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	52600000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	303000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	195013043	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-21822000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-20243000	USD
CY2021	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12546000	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-58365000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-58365000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34368000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-34368000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20243000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20243000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	195013043	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112236110	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112236110	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13893819	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13893819	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.46
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11627794	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5094450	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10375134	shares

Files In Submission

Name	View Source	Status
0001628280-22-004085-index-headers.html	Edgar Link	pending
0001628280-22-004085-index.html	Edgar Link	pending
0001628280-22-004085.txt	Edgar Link	pending
0001628280-22-004085-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20211231.htm	Edgar Link	pending
ocgn-20211231.xsd	Edgar Link	pending
ocgn-20211231x10kxex211.htm	Edgar Link	pending
ocgn-20211231x10kxex231.htm	Edgar Link	pending
ocgn-20211231x10kxex311.htm	Edgar Link	pending
ocgn-20211231x10kxex312.htm	Edgar Link	pending
ocgn-20211231x10kxex321.htm	Edgar Link	pending
ocgn-20211231x10kxex41.htm	Edgar Link	pending
ocgn-20211231x10kxex43.htm	Edgar Link	pending
ocgn-20211231_cal.xml	Edgar Link	unprocessable
ocgn-20211231_def.xml	Edgar Link	unprocessable
ocgn-20211231_g1.jpg	Edgar Link	pending
ocgn-20211231_g10.jpg	Edgar Link	pending
ocgn-20211231_g11.jpg	Edgar Link	pending
ocgn-20211231_g12.jpg	Edgar Link	pending
ocgn-20211231_g13.jpg	Edgar Link	pending
ocgn-20211231_g14.jpg	Edgar Link	pending
ocgn-20211231_g2.jpg	Edgar Link	pending
ocgn-20211231_g3.jpg	Edgar Link	pending
ocgn-20211231_g4.jpg	Edgar Link	pending
ocgn-20211231_g5.jpg	Edgar Link	pending
ocgn-20211231_g6.jpg	Edgar Link	pending
ocgn-20211231_g7.jpg	Edgar Link	pending
ocgn-20211231_g8.jpg	Edgar Link	pending
ocgn-20211231_g9.jpg	Edgar Link	pending
ocgn-20211231_htm.xml	Edgar Link	completed
ocgn-20211231_lab.xml	Edgar Link	unprocessable
ocgn-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2021 Q4 Form 10-K Financial Statement

#000162828022004085 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2021 Q4 Form 10-K Financial Statement

#000162828022004085 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn